BioSpace News Archive

Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020 , Mike Mahoney , chairman and chief executive officer, and Susie

Enclara Pharmacia, the nation’s leading hospice pharmacy services provider, announces the addition of 43 local pharmacy sites in key markets.

MED-EL USA announced today that the U.S. Food and Drug Administration (FDA) has approved the new slim and lightweight RONDO 3 Audio Processor for the SYNCHRONY Cochlear Implant System. MED-EL anticipates that RONDO 3 will be available later this year.

Following PRIMED Medical Products’ (PRIMED) recent announcement on establishing a new major medical manufacturing facility in Canada, today the company reveals Cambridge, Ontario as the chosen location

Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to healthcare services and life sciences companies worldwide, today announced the closing of a

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of dialysis products and services, has activated its national disaster response team to ensure continuity of care as Hur

Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2000th transcatheter heart valve procedure, a milestone innovation that has shifted valve repair and replacement from operating room to catherization lab

The Office of Global Partnerships at the U.S. Department of State, the University of Virginia Darden School of Business Institute for Business in Society and Concordia announced Asili, a transformative social enterprise model conceived by Alight and subsidiary Eastern Congo Initiative (ECI), as one of five finalists for the 2020 P3 Impact Award.

Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced the publication of results from a Phase 2 clinical study of its oral antifungal product candidate oteseconazole (VT-1161) for the treatment of acute vulvovaginal candidiasis (VVC). The results demonstrated that oteseconazole was safe and well tolerated in women with mode

Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. In addition, Maxim Group LLC has exercised its over-allotment option to purchase 116,835 shares of common stock, at the public offering price less underwriting discounts. Gross proceeds before deductin